(Health-NewsWire.Net, July 26, 2017 ) Constipation refers to the infrequent or difficult passing of stool. Constipation occurs when bowel movements become difficult or less frequent. Symptoms of constipation include swollen abdomen or abdominal pain pain and vomiting. The predisposing factors include eating disorders irritable bowel syndrome and hypothyroidism overuse of laxatives (stool softeners) which over time weaken the bowel muscles stress inadequate water intake and inadequate fiber in the diet. Treatment includes use of laxatives and proper lifestyle.
Report Highlights Pharmaceutical and Healthcare latest pipeline guide Constipation-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Constipation (Gastrointestinal) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.
The Constipation (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Constipation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Pre-Registration Phase III Phase II Phase I Preclinical and Discovery stages are 4 6 10 2 3 and 1 respectively. Similarly the Universities portfolio in Discovery stages comprises 1 molecules respectively.
Constipation (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Constipation (Gastrointestinal) . - The pipeline guide reviews pipeline therapeutics for Constipation (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities. - The pipeline guide reviews key companies involved in Constipation (Gastrointestinal) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Constipation (Gastrointestinal) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Constipation (Gastrointestinal)
- Procure strategically important competitor information analysis and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Constipation (Gastrointestinal) . - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Constipation (Gastrointestinal) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles Albireo Pharma Inc Allergan Plc Ardelyx Inc Astellas Pharma Inc Braintree Laboratories Inc Dong-A ST Co. Ltd. EA Pharma Co Ltd Ironwood Pharmaceuticals Inc Johnson & Johnson Kissei Pharmaceutical Co Ltd NGM Biopharmaceuticals Inc RaQualia Pharma Inc Sanwa Kagaku Kenkyusho Co Ltd SK Biopharmaceuticals Co Ltd Sucampo Pharmaceuticals Inc Sumitomo Dainippon Pharma Co Ltd
List of Tables Number of Products under Development for Constipation H2 2017 Number of Products under Development by Companies H2 2017 Number of Products under Development by Companies H2 2017 (Contd..1) H2 2017 Number of Products under Development by Universities/Institutes H2 2017 Products under Development by Companies H2 2017 Products under Development by Companies H2 2017 (Contd..1) H2 2017 Products under Development by Universities/Institutes H2 2017 Number of Products by Stage and Target H2 2017 Number of Products by Stage and Mechanism of Action H2 2017 Number of Products by Stage and Route of Administration H2 2017 Number of Products by Stage and Molecule Type H2 2017 Constipation-Pipeline by Albireo Pharma Inc H2 2017 Constipation-Pipeline by Allergan Plc H2 2017 Constipation-Pipeline by Ardelyx Inc H2 2017 Constipation-Pipeline by Astellas Pharma Inc H2 2017 Constipation-Pipeline by Braintree Laboratories Inc H2 2017 Constipation-Pipeline by Dong-A ST Co. Ltd. H2 2017 Constipation-Pipeline by EA Pharma Co Ltd H2 2017 Constipation-Pipeline by Ironwood Pharmaceuticals Inc H2 2017 Constipation-Pipeline by Johnson & Johnson H2 2017